PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas

Researchers reveal the risks of laryngeal edema after chimeric antigen receptor T-cell therapy for relapsed or refractory B-cell lymphomas

Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas
2024-12-17
(Press-News.org)

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients’ T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize specific targets on cancer cells, allowing these T-cells to locate and destroy the cancer cells. CAR T-cell therapy shows promising results in treating relapsing or refractory B-cell lymphomas. To explore the risks associated with CAR T-cell therapy, researchers from Juntendo University, Japan, including Professor Jun Ando, Professor Miki Ando, and Dr. Erina Hosoya, published a study in Haematologica on October 17, 2024.

 

Elaborating about this study further, Dr. Hosoya, the study's lead author, says, “We conducted a single-center, retrospective analysis of 59 patients with relapsed/refractory B-cell lymphoma enrolled for CAR T-cell therapy with tisagenlecleucel (tisa-cel) between September 2020 and September 2023. Forty-one study patients (38 with diffuse large B-cell lymphoma (DLBCL) and three with follicular lymphoma (FL)) received an infusion of tisa-cel. Response assessments were completed in 37 patients with DLBCL and one with FL.” The team tracked overall survival (OS) and progress-free survival (PFS) over 12 months, finding OS at 73.8% and PFS at 49.6%.  Safety monitoring showed that 30 out of 41 patients who received tisa-cel developed cytokine release syndrome (CRS), an inflammatory side effect. Of these, 14 patients had more severe CRS (grade 3 or higher) and also tended to receive higher doses of CAR-positive cells, leading to earlier fevers compared to those with milder (grade 1 or 2) CRS.

 

The researchers identified 11 laryngeal edemas in patients as a serious and previously unrecognized side effect of CAR T-cell therapy. Initially thought to affect only those with neck tumors, it was found in all patients, regardless of tumor location. Intensive care and airway management were provided due to the obstruction caused by the edema. This condition typically developed within 3.4 days post-infusion and resolved within 14 days for all patients.

 

Explaining these results, Dr. Hosoya says, “Although a few case reports of laryngeal edema with tisa-cel treatment for B-cell lymphoma have appeared, the mechanism of this phenomenon is still unknown and no established management guidelines exist despite the major risk of life-threatening airway obstruction. We, therefore, assessed risk factors for the occurrence of laryngeal edema and the influence of steroid treatment on both CAR T-cell expansion and clinical outcome.” The research team identified a key risk factor for laryngeal edema—patients who experienced this condition had a significantly higher number of CAR-positive cells infused (4.0 x 108 vs 3.3 x 108). They found that infusions with more than 3.4 x 108 CAR-positive cells could predict the risk of laryngeal edema. Additionally, the CAR T-cells from patients with laryngeal edema contained a higher proportion of effector T-cells compared to those without edema. Sharing another interesting observation from the study, Dr. Hosoya says, “Our impression clinically was that the frequency of laryngeal edema after tisa-cel infusion rose in the summer of 2022. So, we attempted to coordinate the date of tisa-cel manufacture with the occurrence of laryngeal edema.” This observation was a result of the high numbers of CAR-positive cells in products manufactured after June 2022 than in those manufactured before June 2022.

 

Based on these observations from the study, the team of researchers concludes that using steroids, such as dexamethasone, could prove effective for early management of laryngeal edema. They found that administering steroids provided relief to patients without reducing the effectiveness of CAR T-cell therapy.

 

In summary, these findings highlight the serious adverse effects of tisa-cel therapy, its associated risk factors, and management strategies for improving patient safety and treatment experiences. Concluding optimistically, Dr. Hosoya says, “We believe that our analyses encompass both efficacy and safety with tisa-cel therapy in real-world settings.”

 

Reference

Authors

Erina Hosoya1, Jun Ando1,2, Shintaro Kinoshita1, Yoshiki Furukawa1, Yuko Toyoshima1,2, Yoko Azusawa2, Toru Mitsumori3, Eriko Sato4, Hina Takano5, Yutaka Tsukune1, Naoki Watanabe1, Tomoiku Takaku1, Hajime Yasuda1, Yasuharu Hamano1, Makoto Sasaki1, Shuko Nojiri6 , Midori Ishii1, and Miki Ando1

Title of original paper

Eleven Cases of Laryngeal Edema After Tisagenlecleucel Infusion: A 3-year Single Center Retrospective Study of CD19-directed Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory B-cell Lymphomas

Journal

Haematologica

DOI

10.3324/haematol.2024.286169

Affiliations

1Department of Hematology, Juntendo University School of Medicine

2Division of Cell Therapy & Blood Transfusion Medicine, Juntendo University School of Medicine

3Department of Hematology, Juntendo University Urayasu Hospital

4Department of Hematology, Juntendo University Nerima Hospital

5Department of Hematology, Juntendo University Shizuoka Hospital

6Medical Technology Innovation Center, Juntendo University, Japan

 

About Dr. Erina Hosoya  

Dr. Erina Hosoya is a graduate student at the Department of Hematology at the Juntendo University School of Medicine, Tokyo, Japan, and works with Professor Miki Ando and Professor Jun Ando. Dr. Hosoya’s main research interests are in the fields of Clinical Genetics, Clinical Oncology, Cancer Immunotherapy, Stem Cell Transplantation Studies, and Hematology. She has been a part of three research papers this year with her team at the Department of Hematology, Juntendo University, and has won the Excellent Poster Award at the 16th Kanto-Koshinetsu Regional Conference by the Japanese Society of Hematology.

END


[Attachments] See images for this press release:
Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas 2 Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas 3

ELSE PRESS RELEASES FROM THIS DATE:

Event Horizon Telescope: Moving towards a close-up of a black hole and its jets

2024-12-17
After taking the first images of black holes, the ground-breaking Event Horizon Telescope (EHT) is poised to reveal how black holes launch powerful jets into space. Now, a research team led by Anne-Kathrin Baczko from Chalmers University of Technology in Sweden has shown that the EHT will be able to make exciting images of a supermassive black hole and its jets in the galaxy NGC 1052. The measurements, made with interconnected radio telescopes, also confirm strong magnetic fields close to the black hole’s edge.  The main research question for the project’s ...

USC Norris Cancer Hospital earns Leapfrog Top Hospital award for fourth year in a row

USC Norris Cancer Hospital earns Leapfrog Top Hospital award for fourth year in a row
2024-12-17
LOS ANGELES — USC Norris Cancer Hospital was named a Top Teaching Hospital by The Leapfrog Group, a leading national patient safety watchdog organization, for the fourth consecutive year.     “The Leapfrog Top Hospital award is one of the most competitive awards a hospital can receive, and we are delighted that USC Norris Cancer Hospital places among the highest-rated hospitals in the nation once again,” said Marty Sargeant, MBA, CEO of Keck Medical Center of USC, which includes USC Norris Cancer Hospital.     To qualify for the distinction, hospitals must rank top among peers ...

New insights into blood vessel formation

New insights into blood vessel formation
2024-12-17
The formation of blood vessels is a complex process involving the interplay of proteins and mechanic forces. In two studies, a research team at the Biozentrum of the University of Basel, Switzerland, has uncovered new mechanisms in blood vessel formation. The team demonstrated how cells interact during vascular lumen formation and the critical role of dynamic forces in this process. These new insights into blood vessel formation may provide potential approaches in the treatment of vascular diseases. Blood vessels run throughout the entire body, delivering nutrients and oxygen through the circulating blood. During vessel formation, cells first form local ...

Described in Mallorca the world's oldest ancestor of mammals

Described in Mallorca the worlds oldest ancestor of mammals
2024-12-17
Gorgonopsians are an extinct group of synapsids that lived during the Permian, between 270 and 250 million years ago. They belong to the evolutionary lineage that would give rise to the first mammals 50 million years later. They were warm-blooded animals like modern mammals, but, unlike most of them, they laid eggs. They were carnivorous and were the first animals to develop the characteristic saber teeth. They were often the superpredators of the ecosystems in which they lived, and their appearance would be similar to a dog, ...

Fossil predator is the oldest known animal with “saber teeth”

Fossil predator is the oldest known animal with “saber teeth”
2024-12-17
The first true mammals evolved roughly 200 million years ago, during the early days of the dinosaurs. But mammals are the last surviving members of an older group, called the therapsids. At first glance, many therapsids weren’t obviously mammal-like , but they also had subtle features that we recognize in mammals today, like a hole on the sides of their skull for the jaw muscle to attach and structures on their jaw bones that would eventually evolve into mammals' distinctive middle ear bones. In a new paper in the journal Nature Communications, scientists announce the discovery of a fossil therapsid ...

Scientists develop new scans that light-up aggressive cancer tumors for better treatment

2024-12-17
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer. The authors at King’s College London say that using the radiotracer – an injected compound used in PET scans – could help inform doctors that a patients aggressive cancer will not respond to chemotherapy before treatment is given. This would prevent the patients receiving unnecessary treatment and provide them with alternative options that will give them the best chance of beating the disease. The ...

The longevity factor Foxo3 mediates “unfit” cell elimination to ensure healthy body construction

The longevity factor Foxo3 mediates “unfit” cell elimination to ensure healthy body construction
2024-12-17
Osaka, Japan – From the very moment an egg is fertilized, life begins with a remarkable process: cells start dividing and replicating to make copies of themselves. Yet this process is not flawless. Errors can occur when genetic material is copied, creating “unfit” cells that don’t work properly. To keep development on track, cells employ a fascinating quality control system called cell competition. However, much about this mechanism remains unclear. Now, in a study recently published in Nature ...

Researchers demonstrate high accuracy of observation device that can be dropped into typhoon without parachute

Researchers demonstrate high accuracy of observation device that can be dropped into typhoon without parachute
2024-12-17
Researchers in Japan have demonstrated the high accuracy of their newly developed typhoon observation device, which is designed to drop from an aircraft into the eye of a typhoon. The results were published in the journal Scientific Online Letters on the Atmosphere (SOLA). Dropped from aircraft, the dropsonde, a small, single-use instrument, measures and transmits atmospheric data, including temperature, humidity, and wind speed, as it falls. The new dropsonde, iMDS-17, weighs only 130 grams and is made mainly of a biodegradable ...

Positive results of the clinical trial of a drug to improve cognitive function in Down syndrome

2024-12-17
The ICOD (Improving Condition in Down syndrome) project, a pioneering study in addressing the cognitive difficulties associated with Down syndrome, has demonstrated the safety of treatment with the molecule AEF0217, developed by the French biotech Aelis Farma, as well as its effectiveness in improving cognitive function in these people. The study was led by the Research Institute of the Hospital del Mar.  This phase of the trial (phase 1/2 of the project), funded by the European Union under the Horizon 2020 R+D programme and Aelis Farma, has been carried out with 29 people with Down syndrome between 18 and ...

Insurance challenges limit psychologists’ capacity to address ongoing mental health needs

2024-12-17
Although demand for mental health treatment remains high, administrative and financial barriers are preventing many psychologists from participating in insurance networks, according to the American Psychological Association’s 2024 Practitioner Pulse Survey. Barriers by many insurance companies can make it more difficult for psychologists to remain in-network and for patients to access the care they need, exacerbating the ongoing mental health crisis. This annual survey, which was conducted among 853 psychologists in September 2024, by APA and its companion organization APA Services ...

LAST 30 PRESS RELEASES:

Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training

Day-long conference addresses difficult to diagnose lung disease

First-ever cardiogenic shock academy features simulation lab

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

[Press-News.org] Risks of tisagenlecleucel therapy for relapsed or refractory b-cell lymphomas
Researchers reveal the risks of laryngeal edema after chimeric antigen receptor T-cell therapy for relapsed or refractory B-cell lymphomas